Amicus Therapeutics is a Cranbury, New Jersey biopharmaceutical company that has been led by CEO John Crowley since 2005. It has publicly operated since 2007. Amicus primarily does research and development for medicines and treatments of rare and orphan diseases. In particular, they are focused on developing new enzyme replacement therapies. Its most promising drug at present is migalastat, which is a major component for treatment of Fabry Disease. It also has promising drugs in development for Pompe Disease, the skin disorder known as Epidermolysis Bullosa, and various Lysosomal Storage Disorders.
It had some measure of financial success in the earliest years, but it was really given a boost in 2010 with two huge grants: $500,000 from The Michael J. Fox Foundation and $210,300 from the Alzheimer’s Drug Discovery Foundation. During that same year, Amicus saw several key changes in leadership: Crowley assumed the role of Amicus Therapeutics Chairman of the Board, David Lockhart became the Chief Scientific Officer, and Brandon Wustman became the Director of Exploratory Biology. From that point forward Amicus Therapeutics kept growing in a big way (YahooFinance).
In 2013, it acquired and absorbed Callidus Biopharma, a major competitor (https://www.crunchbase.com/organization/amicus-therapeutics). Then in 2015 it acquired and absorbed Amicus Therapeutics is fully capable of research and development; however, it does not have the facilities or equipment to mass manufacture these drugs on its own. That is why it contracts with manufacturers to do so. However, they are today at the top in the international industry at what they do. But the company intends to seek further frontiers and to explore other ways of bettering itself so that it can in turn better help the world. Above all else, its goal is to create it into a healthier one. Amicus Therapeutics has an abundance of great information and contact details on its website at www.amicusrx.com.